IFTB.F Stock Overview
A clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.20 |
| 52 Week High | SEK 8.38 |
| 52 Week Low | SEK 7.47 |
| Beta | 1.13 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 9.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| IFTB.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | n/a | 14.2% | 32.3% |
Return vs Industry: Insufficient data to determine how IFTB.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IFTB.F performed against the US Market.
Price Volatility
| IFTB.F volatility | |
|---|---|
| IFTB.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IFTB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IFTB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| IFTB.F fundamental statistics | |
|---|---|
| Market cap | US$122.85m |
| Earnings (TTM) | -US$11.90m |
| Revenue (TTM) | US$6.39k |
Over9,999x
P/S Ratio-10.3x
P/E RatioIs IFTB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IFTB.F income statement (TTM) | |
|---|---|
| Revenue | SEK 69.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 69.00k |
| Other Expenses | SEK 128.48m |
| Earnings | -SEK 128.41m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
| Earnings per share (EPS) | -9.53 |
| Gross Margin | 100.00% |
| Net Profit Margin | -186,108.70% |
| Debt/Equity Ratio | 0% |
How did IFTB.F perform over the long term?
See historical performance and comparison